Retrophin, Inc.

Retrophin, Inc.

Retrophin, Inc.

Overview
Date Founded

2008

Headquarters

3721 Valley Centre Drive, Suite 200, San Diego, CA, 92130, USA

Type of Company

Public

Employees (Worldwide)

214

Industries

Biotechnology
Hospitals & Patient Services
Pharmaceuticals
Medical Support Services

Company Description

Retrophin, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Contact Data
Trying to get in touch with decision makers at Retrophin, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Chief Financial & Accounting Officer

Senior Vice President, General Counsel & Corporate Secretary

Chief Commercial Officer

Chief Medical Officer

Senior Vice President, Head-Research & Development

Executive Director Business de

Senior Director, Investor Relations

Director of Medical Strategy

Director of Clinical Logistics

Board of Directors

Former President & Chief Executive Officer at Neurocrine Biosciences Inc.

Chief Medical Officer at Merck & Co., Inc.

Vice Chairman & Chief Executive Officer at Intec Pharma Ltd.

Director, President & Chief Executive Officer at Atreca, Inc.

Former Vice President-Financial Services at California Healthcare Institute

Chief Executive Officer at Kyalin Biosciences, Inc.

President & Chief Executive Officer at Retrophin, Inc.

Chief Operating Officer at Advantagene, Inc.

Former Chief Executive Officer & Director at Array BioPharma Inc.

Paths to Retrophin, Inc.
Potential Connections via
Relationship Science
You
Retrophin, Inc.
Owners & Shareholders
Details Hidden

RA Capital Management, LLC (“RA Capital”) is a crossover fund manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with minimal capital concerns from inception through commercialization.

Details Hidden

SCM employs a fundamentals-based, value-driven investment approach across four strategies: a long-short equity strategy managed with the discipline of market neutrality, a long-short equity strategy managed with net long exposure, a long-only equity strategy and a long-short health care focused strategy. The firm seeks to identify investments primarily in publicly-traded equities (on both US and non-US exchanges), including IPOs, but may also include options, derivatives and bonds that they believe will increase in value (or at least maintain their value) even in a falling market, and conversely to identify and sell short stocks that they believe will drop in value (or at least under-perform) regardless of the industry and the market's overall direction. The long portfolio focuses on dynamic companies protected by low valuations relative to free cash flow, strong cash positions or valuable intellectual property and sensible business models. The short portfolio selects companies that SCM determines are not only overvalued, but also fundamentally flawed because of the poor prospects of their products or services. The research process combines examining publicly available financial data and conducting in-depth proprietary field research.

Details Hidden

Perceptive Advisors focuses on investment opportunities in healthcare, with an emphasis on biotechnology. The firm believes that significant opportunities exist in biotechnology due to pervasive underlying market inefficiencies and volatility. Perceptive Advisors advises two separate master-feeder private fund structures.The Perceptive Life Sciences Funds invest in the equities of growth healthcare companies and value plays, with an emphasis on biotechnology. Perceptive Advisors seeks to identify opportunities to exploit relative value disparities and inefficiencies that exist on both the long and short side of the market. They focus on a universe of about 300 smaller, more inefficiently priced companies which are underfollowed by Wall Street biotechnology analysts. Hedging strategies using long and short equity positions, equity options, and index options are used in an attempt to reduce and control risk.The Perceptive Credit Opportunity Fund seeks to achieve superior risk-adjusted returns by investing in senior secured loans and other debt and debt-related instruments issued by small- and mid-cap publicly traded companies and privately-held emerging growth companies primarily in the healthcare and related industries. The fund's investments may be originated by the fund or in collaboration with a syndicate of other credit investors. Most of the fund's investments will be structured as directly originated loans to healthcare companies.Perceptive Advisors also advises two separate accounts. The investment strategies of the separate accounts are substantially similar to those of the Perceptive Life Sciences Fund, though the separate accounts may take more concentrated positions and use a higher degree of leverage.

Recent Transactions
Details Hidden

Retrophin, Inc. issued Common Stock

Details Hidden

Retrophin, Inc. issued Common Stock

Details Hidden

Retrophin, Inc. raised money in a private placement transaction

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Underwriter

Advised onRetrophin, Inc. issued Common Stock

Auditor

Advised onRetrophin, Inc. issued Common Stock

Underwriter

Advised onRetrophin, Inc. issued Common Stock

Senior Managing Director

Advised onRetrophin, Inc. issued Common Stock

Managing Director

Advised onRetrophin, Inc. issued Common Stock

Legal Advisor

Advised onRetrophin, Inc. issued Common Stock

Advisors & Consultants
Consultant

President & Chief Executive Officer at Disarm Therapeutics, Inc.

Legal Advisor

Attorney at Goodwin Procter LLP

Consultant

Former Vice President, Clinical Development & Medical Affairs at Genzyme Corp.

Clients

EVERSANA Life Science Services LLC engages in the provision of global services to the life science industry. It offers pricing, reimbursement and market access, global channel management, revenue management, and affordability programs. The company is headquartered in Milwaukee, WI.

Key Stats and Financials As of 2018
Market Capitalization
$647M
Total Enterprise Value
$661M
Earnings Per Share
$-2.54
Net Profit
$-103M
EBITDA
$-50M
EBITDAMargin
-30.46%
Total Debt
$218M
Total Equity
$318M
Enterprise Value Sales
4.02x
TEVNet Income
-6.44x
Debt TEV
0.33x
Revenue
$164M
Three Year Compounded Annual Growth Rate Of Revenue
18.03%
Investments
Details Hidden

Perlara PBC manufactures orphan drugs. It solves the unmet medical needs of orphan disease patients with a scalable drug candidate generator that leaves no mutation behind. The company was founded by Ethan Perlstien in February 2014 and is headquartered in San Francisco, CA.

Suppliers
Ligand Pharmaceuticals, Inc. Medical Support Services | LA JOLLA , CA

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

Nexgen Pharma (TM), Inc. Pharmaceuticals | Irvine, CA

Nexgen Pharma (TM), Inc. manufactures and develops drugs. The firm also offers pharmaceutical product development, dietary supplement formulation, process and cleaning validation and many other services. The company was founded by J. W. Wigelsworth in 1925 and is headquartered in Irvine, CA.

Mission Pharmacal Co. Pharmaceuticals | San Antonio, TX

Mission Pharmacal Co. manufactures pharmaceutical products. Its products include Flowtuss, Hycofenix, Thera-Gesic, Oncovite, Maxilube, Heat Guard, Foseree and Texacort. The company's capabilities include research and development, laboratory, manufacturing, packaging, warehousing and distribution and international services. Mission Pharmacal was founded in 1946 by H. N. Walsdorf and is headquartered in San Antonio, TX.

Competitors
Pfizer, Inc. Pharmaceuticals - New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Novartis AG Pharmaceuticals - Basel, BS

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following four segments: Innovative Medicines, Alcon, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Alcon segment researches, develops, manufactures, distributes and sells eye care devices and vision care. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Bristol-Myers Squibb Company Pharmaceuticals - New York, New York

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Retrophin, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Retrophin, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Retrophin, Inc..